FGD3 and breast cancer: In a follow-up study, the group developed a breast cancer prognostic test, Breast Cancer Attractor Metagenes (BCAM), which had several molecular features, including the breast cancer–specific FGD3-SUSD3 metagene, as well as tumor size, and number of positive lymph nodes.41